CCS to license CEVEC Pharma protein production technology
The technology will enable CCS to provide its customers with transfected non-tumor origin cell lines including CAP-TTM cells, designed for use in cell based assays and protein production
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.